{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:40:24Z","timestamp":1730392824586,"version":"3.28.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.canrad.2024.07.010","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T10:59:18Z","timestamp":1728471558000},"page":"513-518","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Essais qui changent les pratiques\u00a0: cancers urologiques"],"prefix":"10.1016","volume":"28","author":[{"given":"Pierre","family":"Graff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Minsat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2024.07.010_bib0105","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2023.06.210","article-title":"Long-term outcomes of NRG\/RTOG 0126, a randomized trial of high dose (79.2Gy) vs. standard dose (70.2Gy) radiation therapy (RT) for men with localized prostate cancer","volume":"117","author":"Michalski","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0110","doi-asserted-by":"crossref","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80\u00a0vs. 70Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18\u00a0randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0115","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.07.010_bib0120","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0125","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and comorbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijrobp.2023.05.014","article-title":"Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the Prostate Cancer Study-5, a Groupe de radio-oncologie g\u00e9nito-urinaire de Qu\u00e9bec-led phase 3\u00a0trial","volume":"118","author":"Niazi","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.07.010_bib0135","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypofractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"Van As","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2023.41.6_suppl.298","article-title":"PACE-A: an international phase 3\u00a0randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)\u00a0\u2014\u00a0primary endpoint analysis","volume":"41","author":"Van As","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0145","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0150","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.22.02389","article-title":"Dose-escalated radiation alone or in combination with short-term total androgen suppression for intermediate-risk prostate cancer: patient-reported outcomes from NRG\/Radiation Therapy Oncology Group 0815\u00a0randomized trial","volume":"41","author":"Movsas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0155","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for non-metastatic prostate cancer (SANDSTORM): a pooled analysis of 12\u00a0randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0160","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6\u00a0months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.010_bib0165","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.010_bib0170","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.23.01391","article-title":"Salvage reirradiation for locally recurrent prostate cancer: results from a prospective study with 7.2\u00a0years of follow-up","volume":"42","author":"Ekanger","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: phase 1\u00a0results from the G\u00e9tug-Afu 31\u00a0study","volume":"6","author":"Pasquier","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0180","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.07.010_bib0185","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND Phase 2\u00a0randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0190","doi-asserted-by":"crossref","first-page":"LBA5000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5000","article-title":"Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3\u00a0randomized trial with a 2\u00d72\u00a0design","volume":"41","author":"Bossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0195","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.07.010_bib0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03\u00a0FASTRACK II): a non-randomised phase 2\u00a0trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:18:47Z","timestamp":1730391527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824001367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":20,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1278321824001367"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2024.07.010","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Essais qui changent les pratiques\u00a0: cancers urologiques","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2024.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}